SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-22-000016
Filing Date
2022-05-10
Accepted
2022-05-10 16:16:37
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K tars-20220510.htm   iXBRL 8-K 35639
2 EX-99.1 exhibit991tarsus5122022pre.htm EX-99.1 102513
6 picture1a.jpg GRAPHIC 5866
  Complete submission text file 0001819790-22-000016.txt   298061

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20220510.xsd EX-101.SCH 1890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20220510_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20220510_pre.xml EX-101.PRE 13035
8 EXTRACTED XBRL INSTANCE DOCUMENT tars-20220510_htm.xml XML 11334
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 22909843
SIC: 2836 Biological Products, (No Diagnostic Substances)